Evidence map›Paper›PMID 33264327›Full record

Observational studyPloS one2020

Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer.

Damian J Mole, Jonathan A Fallowfield, Ahmed E Sherif, Timothy Kendall, Scott Semple, Matt Kelly, Gerard Ridgway, John J Connell, John McGonigle, Rajarshi Banerjee and 13 more

3 registry-linked trialsOpen access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03213314 nacompletednot on this map

HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies

TypeinterventionalSponsorUniversity of EdinburghRan2017 to 2019Enrolled149ConditionsLiver Cancer, Surgery, Liver Regeneration, Colorectal Cancer MetastaticArmsMultiparameter magnetic resonance imaging
NCT06144827 nawithdrawnnot on this mapstarted 2025, after this paper: background citation

Pilot Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer

TypeinterventionalSponsorMontefiore Medical CenterRan2025 to 2028Enrolled0ConditionsCancer, Hepatocellular, Radiotherapy Side EffectArmsMultiparametric MRI scans, Multiparametric MRI scans + HepQuantShunt Test
NCT06899152 narecruitingnot on this mapstarted 2025, after this paper: background citation

HepQuant: Pilot Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer

TypeinterventionalSponsorMontefiore Medical CenterRan2025 to 2031Enrolled40ConditionsLiver Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, CholangiocarcinomaArmsHepQuant DuO, Multiparametric MRI Scans
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 2 countries.

Damian J MoleClinical Surgery, Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh, United Kingdom.
Jonathan A FallowfieldCentre for Inflammation Research, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, United Kingdom.ORCID 0000-0002-5741-1471
Ahmed E SherifClinical Surgery, Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0002-8469-8148
Timothy KendallInstitute of Genetics and Molecular Medicine, Edinburgh, United Kingdom.
Scott SempleCentre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom.
Matt KellyPerspectum, Gemini One, Oxford, United Kingdom.ORCID 0000-0002-5834-635X
Gerard RidgwayPerspectum, Gemini One, Oxford, United Kingdom.
John J ConnellPerspectum, Gemini One, Oxford, United Kingdom.ORCID 0000-0002-7756-9997
John McGoniglePerspectum, Gemini One, Oxford, United Kingdom.
Rajarshi BanerjeePerspectum, Gemini One, Oxford, United Kingdom.
J Michael BradyPerspectum, Gemini One, Oxford, United Kingdom.
Xiaozhong ZhengCentre for Inflammation Research, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, United Kingdom.
Michael HughesClinical Surgery, Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh, United Kingdom.
Lucile NeytonCentre for Inflammation Research, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, United Kingdom.
Joanne McClintockHampshire Hospitals Foundation Trust, Basingstoke, United Kingdom.
Garry TuckerClinical Research Facility, NHS Lothian, Edinburgh, United Kingdom.
Hilary NailonClinical Research Facility, NHS Lothian, Edinburgh, United Kingdom.
Dilip PatelClinical Radiology, NHS Lothian, Edinburgh, United Kingdom.
Anthony WackettEdinburgh Clinical Trials Unit, Edinburgh, United Kingdom.
Michelle StevenEdinburgh Clinical Trials Unit, Edinburgh, United Kingdom.
Fenella WelshHampshire Hospitals Foundation Trust, Basingstoke, United Kingdom.
Myrddin ReesHampshire Hospitals Foundation Trust, Basingstoke, United Kingdom.
HepaT1ca Study Group
NHS Lothian · GBEdinburgh Royal Infirmary · GBHampshire Hospitals NHS Foundation Trust · GBQueen's Medical Centre · GBThe Queen's Medical Research Institute · GB

Funding

Chief Scientist Office SCD/20Medical Research Council G0701127Medical Research Council MR/P008887/1
6 · The paper itself

Abstract

The risk of poor post-operative outcome and the benefits of surgical resection as a curative therapy require careful assessment by the clinical care team for patients with primary and secondary liver cancer. Advances in surgical techniques have improved patient outcomes but identifying which individual patients are at greatest risk of poor post-operative liver performance remains a challenge. Here we report results from a multicentre observational clinical trial (ClinicalTrials.gov NCT03213314) which aimed to inform personalised pre-operative risk assessment in liver cancer surgery by evaluating liver health using quantitative multiparametric magnetic resonance imaging (MRI). We combined estimation of future liver remnant (FLR) volume with corrected T1 (cT1) of the liver parenchyma as a representation of liver health in 143 patients prior to treatment. Patients with an elevated preoperative liver cT1, indicative of fibroinflammation, had a longer post-operative hospital stay compared to those with a cT1 within the normal range (6.5 vs 5 days; p = 0.0053). A composite score combining FLR and cT1 predicted poor liver performance in the 5 days immediately following surgery (AUROC = 0.78). Furthermore, this composite score correlated with the regenerative performance of the liver in the 3 months following resection. This study highlights the utility of quantitative MRI for identifying patients at increased risk of poor post-operative liver performance and a longer stay in hospital. This approach has the potential to inform the assessment of individualised patient risk as part of the clinical decision-making process for liver cancer surgery.

Indexed as

HepatectomyLiver RegenerationAdenocarcinomaAgedBile Duct NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaEmbolization, TherapeuticFemaleHumansHypertrophyLiverLiver DiseasesLiver NeoplasmsMagnetic Resonance ImagingMale

Identifiers

PMID33264327
PMCPMC7710097
OpenAlexW3098780148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.